Stock Ratings / Health Care / TYRA / financials

GHRS (58) PCRX (54) ANAB (61) ETON (62) ⌘ Pro Terminal →

Tyra Biosciences Inc. (TYRA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$21.48 -1.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.39

Tyra Biosciences Inc. (TYRA) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.39 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TYRA)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY TYRA SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$19.94-7.1% Next Q

Q2 (-2Q)

Grade E$18.52+10.4% Next Q

Q3 (-1Q)

Grade E$20.45+5% Next Q

Current

Grade D-$21.48-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TYRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TYRA currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.67) and Max Pain ($22.55) forces dealer call-delta covering toward $42.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TYRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TYRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TYRA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3.3%	-$119.9M	-$95.3M	-45%
FY 2024	$4.00B	52%	-2.6%	-$86.5M	-$70.4M	-32.8%
FY 2023	$4.00B	52%	-2%	-$69.1M	-$50.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TYRA)

✓Walkthrough of TYRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TYRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.19%▼ DESCENDING CHANNEL

2026-10-30O $21.18H $21.55L $20.32C $21.48VOL 625.8K

RES: $24.01SUP: $15.02SMA50: $22.67SMA200: $29.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TYRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TYRA Butterfly Map → + Track TYRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TYRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TYRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TYRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TYRA)

Health Care Rank #605 of 1016 ⚔️ GHRS vs TYRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TYRA vs. GHRS, PCRX, ANAB, ETON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tyra Biosciences Inc. (TYRA) ranks #605 by composite RQD confidence (41/100, grade D-) and #306 by equity capitalization ($1.48B). Within this direct 5-issuer industry benchmark cohort, TYRA leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ETON currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with TYRA at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TYRA ACTIVE Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	Benchmark Subject
GHRS GH Research PLC	D+	58/100	—	—	—	+3.82%	$1.47B	/ghrs-vs-tyra →
PCRX Pacira BioSciences Inc.	D+	54/100	—	79.4%	1.7%	0.00%	$1.45B	/pcrx-vs-tyra →
ANAB AnaptysBio Inc.	C-	61/100	—	—	85.0%	-3.68%	$1.44B	/anab-vs-tyra →
ETON Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-tyra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001863127

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tyra Biosciences Inc. (TYRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$119.9M, operating cash flow of -$95.1M, and free cash flow of -$95.3M (-35.3% YoY). On the balance sheet, TYRA closed FY2025 with $282.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$119.9M	-$95.1M	-$95.3M	$282.6M	—
FY2024 (FY)	2024-12-31	$0	-$86.5M	-$69.8M	-$70.4M	$363.6M	—
FY2023 (FY)	2023-12-31	$0	-$69.1M	-$50.1M	-$50.1M	—	—

3. TYRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TYRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tyra Biosciences Inc. (NASDAQ: TYRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $21.48 (-1.24% 1D, market cap $1.48B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TYRA ranks #605 in composite RQD confidence.

How does TYRA compare to GHRS and PCRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TYRA carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GHRS (GH Research PLC) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B) and PCRX (Pacira BioSciences Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B). Among the 5-stock peer group, TYRA leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TYRA?

Per TYRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001863127), Tyra Biosciences Inc. generated $0 in revenue, -$119.9M in net income, and -$95.3M in free cash flow against $282.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TYRA trading relative to its 50-day, 200-day, and 52-week technical levels?

TYRA last traded at $21.48 (-1.24% on volume of 734,915 shares), positioning the stock -5.25% below its 50-day simple moving average ($22.67) and -28.09% below its 200-day simple moving average ($29.87). Across its 52-week range of $13.35 to $40.65, TYRA sits at the 29.8% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($19.29 to $23.67).

TYRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Tyra Biosciences Inc. (TYRA)?

In FY 2025 (10-K), TYRA converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: TYRA RQD Cockpit TYRA 12M Forecast TYRA Earnings & Move TYRA Dividends & DRIP TYRA Insiders & 13F TYRA Whale Options TYRA Profit Sankey TYRA News & Why